Symbols / FDMT Stock $8.60 -1.04% 4D Molecular Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
FDMT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. David H. Kirn M.D.
Exch · Country NMS · United States
Market Cap 449.58M
Enterprise Value 79.22M
Income -160.90M
Sales 88.24M
FCF (ttm) -69.36M
Book/sh 8.64
Cash/sh 7.48
Employees 196
Insider 10d —
IPO Dec 11, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.31
PEG —
P/S 5.09
P/B 0.99
P/C —
EV/EBITDA -0.46
EV/Sales 0.90
Quick Ratio 9.01
Current Ratio 9.34
Debt/Eq 4.54
LT Debt/Eq —
EPS (ttm) -2.57
EPS next Y -3.72
EPS Growth —
Revenue Growth 216.64%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA -21.43%
ROE -34.92%
ROIC —
Gross Margin -145.66%
Oper. Margin -24.16%
Profit Margin -182.34%
Shs Outstand 52.28M
Shs Float 38.84M
Insider Own 3.55%
Instit Own 98.25%
Short Float 26.52%
Short Ratio 16.77
Short Interest 11.99M
52W High 12.34
vs 52W High -30.31%
52W Low 3.37
vs 52W Low 155.57%
Beta 2.76
Impl. Vol. 1.40%
Rel Volume 0.67
Avg Volume 739.27K
Volume 495.22K
Target (mean) $28.22
Tgt Median $29.00
Tgt Low $17.00
Tgt High $36.00
# Analysts 9
Recom Buy
Prev Close $8.69
Price $8.60
Change -1.04%
About

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$28.22
Mean price target
2. Current target
$8.60
Latest analyst target
3. DCF / Fair value
$-23.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.60
Low
$17.00
High
$36.00
Mean
$28.22

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-20 reit HC Wainwright & Co. Buy → Buy $36
2026-03-19 main RBC Capital Outperform → Outperform $35
2026-03-19 main Chardan Capital Buy → Buy $26
2026-01-28 init Barclays — → Overweight $33
2025-12-18 main Chardan Capital Buy → Buy $26
2025-11-11 main RBC Capital Outperform → Outperform $32
2025-11-11 main Barclays Overweight → Overweight $33
2025-11-11 main Chardan Capital Buy → Buy $26
2025-10-21 reit RBC Capital Outperform → Outperform $26
2025-08-12 main Roth Capital Buy → Buy $38
2025-08-12 main Chardan Capital Buy → Buy $25
2025-08-01 main Chardan Capital Buy → Buy $25
2025-07-03 main Chardan Capital Buy → Buy $25
2025-05-09 main Chardan Capital Buy → Buy $25
2025-05-09 main Goldman Sachs Buy → Buy $44
2025-05-09 main Barclays Overweight → Overweight $38
2025-03-10 main B of A Securities Buy → Buy $40
2025-03-04 main Chardan Capital Buy → Buy $28
2025-03-03 main RBC Capital Outperform → Outperform $35
2025-03-03 reit HC Wainwright & Co. Buy → Buy $36
News
RSS: Latest FDMT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-20 GUPTA ASHOO Officer — 1,086 — —
2026-03-20 GUPTA ASHOO Officer — 390 $8.61 $3,358
2025-12-19 GUPTA ASHOO Officer — 1,086 — —
2025-12-19 GUPTA ASHOO Officer — 389 $8.68 $3,377
2025-12-16 BIZILY SCOTT Officer — 1,635 $4.14 $6,769
2025-12-16 BIZILY SCOTT Officer — 1,635 $10.90 $17,822
2025-12-12 THEUER CHARLES P. Director — 9,333 $1.14 $10,640
2025-11-17 BIZILY SCOTT Officer — 1,635 $4.14 $6,769
2025-11-17 BIZILY SCOTT Officer — 1,635 $10.59 $17,315
2025-10-24 BIZILY SCOTT Officer — 1,084 $6.49 $7,035
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
85.21
+230194.59%
0.04
-99.82%
20.72
+562.29%
3.13
Operating Revenue
85.21
+230194.59%
0.04
-99.82%
20.72
+562.29%
3.13
Operating Expense
244.76
+30.27%
187.88
+40.64%
133.59
+18.05%
113.16
Research And Development
195.70
+38.50%
141.30
+45.53%
97.10
+20.99%
80.25
Selling General And Administration
49.06
+5.33%
46.58
+27.63%
36.49
+10.90%
32.91
General And Administrative Expense
49.06
+5.33%
46.58
+27.63%
36.49
+10.90%
32.91
Other Gand A
49.06
+5.33%
46.58
+27.63%
36.49
+10.90%
32.91
Total Expenses
244.76
+30.27%
187.88
+40.64%
133.59
+18.05%
113.16
Operating Income
-159.55
+15.06%
-187.84
-66.43%
-112.87
-2.58%
-110.03
Total Operating Income As Reported
-159.55
+15.06%
-187.84
-66.43%
-112.87
-2.58%
-110.03
EBITDA
-151.92
+16.13%
-181.14
-69.10%
-107.12
-0.91%
-106.15
Normalized EBITDA
-151.92
+16.13%
-181.14
-69.10%
-107.12
-0.91%
-106.15
Reconciled Depreciation
7.62
+13.72%
6.71
+16.63%
5.75
+48.17%
3.88
EBIT
-159.55
+15.06%
-187.84
-66.43%
-112.87
-2.58%
-110.03
Net Income
-140.11
+12.90%
-160.87
-59.53%
-100.84
+6.19%
-107.49
Pretax Income
-140.11
+12.90%
-160.87
-59.53%
-100.84
+6.19%
-107.49
Net Non Operating Interest Income Expense
19.48
-28.00%
27.05
+121.52%
12.21
+374.58%
2.57
Net Interest Income
19.48
-28.00%
27.05
+121.52%
12.21
+374.58%
2.57
Interest Income Non Operating
19.48
-28.00%
27.05
+121.52%
12.21
+374.58%
2.57
Interest Income
19.48
-28.00%
27.05
+121.52%
12.21
+374.58%
2.57
Other Income Expense
-0.04
+51.95%
-0.08
+57.46%
-0.18
-417.14%
-0.04
Other Non Operating Income Expenses
-0.04
+51.95%
-0.08
+57.46%
-0.18
-417.14%
-0.04
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-140.11
+12.90%
-160.87
-59.53%
-100.84
+6.19%
-107.49
Net Income From Continuing Operation Net Minority Interest
-140.11
+12.90%
-160.87
-59.53%
-100.84
+6.19%
-107.49
Net Income From Continuing And Discontinued Operation
-140.11
+12.90%
-160.87
-59.53%
-100.84
+6.19%
-107.49
Net Income Continuous Operations
-140.11
+12.90%
-160.87
-59.53%
-100.84
+6.19%
-107.49
Normalized Income
-140.11
+12.90%
-160.87
-59.53%
-100.84
+6.19%
-107.49
Net Income Common Stockholders
-140.11
+12.90%
-160.87
-59.53%
-100.84
+6.19%
-107.49
Diluted EPS
—
-2.98
-15.50%
-2.58
+22.29%
-3.32
Basic EPS
—
-2.98
-15.50%
-2.58
+22.29%
-3.32
Basic Average Shares
—
53.94
+37.86%
39.13
+20.95%
32.35
Diluted Average Shares
—
53.94
+37.86%
39.13
+20.95%
32.35
Diluted NI Availto Com Stockholders
-140.11
+12.90%
-160.87
-59.53%
-100.84
+6.19%
-107.49
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
566.71
+1.13%
560.38
+64.87%
339.89
+29.81%
261.85
Current Assets
413.13
-5.01%
434.93
+46.65%
296.59
+34.50%
220.51
Cash Cash Equivalents And Short Term Investments
402.65
-5.23%
424.88
+47.41%
288.23
+34.97%
213.55
Cash And Cash Equivalents
60.24
-59.66%
149.34
-40.05%
249.11
+375.84%
52.35
Other Short Term Investments
342.41
+24.27%
275.54
+604.28%
39.12
-75.73%
161.20
Receivables
—
—
—
0.00
Accounts Receivable
—
—
—
0.00
Prepaid Assets
—
—
—
—
Other Current Assets
10.48
+4.22%
10.05
+20.33%
8.36
+20.11%
6.96
Total Non Current Assets
153.58
+22.42%
125.45
+189.71%
43.30
+4.76%
41.34
Net PPE
33.01
-18.71%
40.61
+28.24%
31.66
-10.42%
35.35
Gross PPE
54.29
-5.08%
57.19
+31.19%
43.60
+1.21%
43.08
Accumulated Depreciation
-21.28
-28.30%
-16.59
-39.00%
-11.93
-54.40%
-7.73
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
18.14
-13.91%
21.07
+82.63%
11.54
-11.82%
13.09
Machinery Furniture Equipment
17.68
+2.94%
17.17
+17.58%
14.61
+15.81%
12.61
Construction In Progress
0.00
-100.00%
1.18
+114.91%
0.55
+15.55%
0.48
Other Properties
—
—
11.54
-11.82%
13.09
Leases
18.47
+3.96%
17.76
+5.09%
16.90
+0.00%
16.90
Investments And Advances
111.38
+38.22%
80.58
+635.65%
10.95
+123.19%
4.91
Other Non Current Assets
9.19
+115.63%
4.26
+522.95%
0.68
-36.67%
1.08
Total Liabilities Net Minority Interest
61.05
+22.64%
49.78
+55.26%
32.06
+5.09%
30.51
Current Liabilities
43.98
+50.90%
29.15
+53.81%
18.95
+20.47%
15.73
Payables And Accrued Expenses
38.03
+63.55%
23.25
+49.75%
15.53
+27.37%
12.19
Payables
11.16
+154.42%
4.39
+24.78%
3.52
+5.81%
3.32
Accounts Payable
11.16
+154.42%
4.39
+24.78%
3.52
+5.81%
3.32
Current Accrued Expenses
26.87
+42.42%
18.87
+57.06%
12.01
+35.45%
8.87
Current Debt And Capital Lease Obligation
5.59
-0.80%
5.64
+79.01%
3.15
+18.61%
2.65
Current Capital Lease Obligation
5.59
-0.80%
5.64
+79.01%
3.15
+18.61%
2.65
Current Deferred Liabilities
0.36
+40.08%
0.26
-5.86%
0.27
-69.12%
0.88
Current Deferred Revenue
0.36
+40.08%
0.26
-5.86%
0.27
-69.12%
0.88
Total Non Current Liabilities Net Minority Interest
17.06
-17.29%
20.63
+57.34%
13.11
-11.28%
14.78
Long Term Debt And Capital Lease Obligation
15.82
-16.60%
18.97
+64.63%
11.52
-14.46%
13.47
Long Term Capital Lease Obligation
15.82
-16.60%
18.97
+64.63%
11.52
-14.46%
13.47
Tradeand Other Payables Non Current
—
—
—
—
Non Current Deferred Liabilities
0.74
-29.52%
1.06
+8.74%
0.97
-9.67%
1.08
Non Current Deferred Revenue
0.74
-29.52%
1.06
+8.74%
0.97
-9.67%
1.08
Other Non Current Liabilities
0.14
-28.50%
0.19
-22.18%
0.25
+1080.95%
0.02
Stockholders Equity
505.66
-0.97%
510.61
+65.87%
307.83
+33.07%
231.34
Common Stock Equity
505.66
-0.97%
510.61
+65.87%
307.83
+33.07%
231.34
Capital Stock
0.01
+20.00%
0.01
+25.00%
0.00
+33.33%
0.00
Common Stock
0.01
+20.00%
0.01
+25.00%
0.00
+33.33%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
57.61
+25.80%
45.79
+6.31%
43.08
+32.02%
32.63
Ordinary Shares Number
57.61
+25.80%
45.79
+6.31%
43.08
+32.02%
32.63
Additional Paid In Capital
1,221.23
+12.39%
1,086.57
+50.26%
723.14
+32.20%
547.02
Retained Earnings
-716.30
-24.32%
-576.20
-38.73%
-415.33
-32.06%
-314.49
Gains Losses Not Affecting Retained Earnings
0.73
+217.47%
0.23
+1331.25%
0.02
+101.34%
-1.20
Other Equity Adjustments
0.73
+217.47%
0.23
+1331.25%
0.02
+101.34%
-1.20
Total Equity Gross Minority Interest
505.66
-0.97%
510.61
+65.87%
307.83
+33.07%
231.34
Total Capitalization
505.66
-0.97%
510.61
+65.87%
307.83
+33.07%
231.34
Working Capital
369.15
-9.03%
405.78
+46.16%
277.64
+35.58%
204.78
Invested Capital
505.66
-0.97%
510.61
+65.87%
307.83
+33.07%
231.34
Total Debt
21.41
-12.98%
24.61
+67.72%
14.67
-9.01%
16.12
Capital Lease Obligations
21.41
-12.98%
24.61
+67.72%
14.67
-9.01%
16.12
Net Tangible Assets
505.66
-0.97%
510.61
+65.87%
307.83
+33.07%
231.34
Tangible Book Value
505.66
-0.97%
510.61
+65.87%
307.83
+33.07%
231.34
Available For Sale Securities
111.38
+38.22%
80.58
+635.65%
10.95
+123.19%
4.91
Derivative Product Liabilities
0.36
-12.68%
0.41
+11.11%
0.37
+74.06%
0.21
Investmentin Financial Assets
111.38
+38.22%
80.58
+635.65%
10.95
+123.19%
4.91
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-109.08
+18.95%
-134.59
-77.57%
-75.79
+12.57%
-86.69
Cash Flow From Continuing Operating Activities
-109.08
+18.95%
-134.59
-77.57%
-75.79
+12.57%
-86.69
Net Income From Continuing Operations
-140.11
+12.90%
-160.87
-59.53%
-100.84
+6.19%
-107.49
Depreciation Amortization Depletion
7.62
+13.72%
6.71
+16.63%
5.75
+48.17%
3.88
Depreciation
7.62
+13.72%
6.71
+16.63%
5.75
+48.17%
3.88
Depreciation And Amortization
7.62
+13.72%
6.71
+16.63%
5.75
+48.17%
3.88
Stock Based Compensation
22.02
-15.70%
26.12
+32.80%
19.66
+14.86%
17.12
Operating Gains Losses
-0.05
-148.60%
0.11
-56.33%
0.24
+188.24%
0.09
Gain Loss On Investment Securities
-0.05
-148.60%
0.11
-56.33%
0.24
+188.24%
0.09
Change In Working Capital
6.17
+1049.35%
0.54
-14.76%
0.63
+147.16%
-1.34
Change In Receivables
—
—
0.00
-100.00%
0.05
Changes In Account Receivables
—
—
0.00
-100.00%
0.05
Change In Prepaid Assets
-0.42
+75.04%
-1.70
-21.44%
-1.40
-213.28%
1.24
Change In Payables And Accrued Expense
14.93
+101.83%
7.39
+73.31%
4.27
+403.78%
0.85
Change In Accrued Expense
8.15
+24.95%
6.52
+93.53%
3.37
+35.65%
2.48
Change In Payable
6.77
+677.61%
0.87
-2.79%
0.90
+154.70%
-1.64
Change In Account Payable
6.77
+677.61%
0.87
-2.79%
0.90
+154.70%
-1.64
Change In Other Working Capital
-0.21
-402.90%
0.07
+109.65%
-0.71
+77.16%
-3.13
Change In Other Current Assets
-4.93
-37.74%
-3.58
-5010.00%
-0.07
-536.36%
-0.01
Change In Other Current Liabilities
-3.19
-93.40%
-1.65
-13.63%
-1.45
-348.46%
-0.32
Investing Cash Flow
-92.97
+69.26%
-302.44
-361.36%
115.72
+778.69%
-17.05
Cash Flow From Continuing Investing Activities
-92.97
+69.26%
-302.44
-361.36%
115.72
+778.69%
-17.05
Net PPE Purchase And Sale
-0.54
+85.84%
-3.79
-36.63%
-2.77
+75.98%
-11.54
Purchase Of PPE
-0.54
+85.84%
-3.79
-36.63%
-2.77
+75.98%
-11.54
Capital Expenditure
-0.54
+85.84%
-3.79
-36.63%
-2.77
+75.98%
-11.54
Net Investment Purchase And Sale
-92.44
+69.05%
-298.65
-352.05%
118.49
+2248.86%
-5.51
Purchase Of Investment
-442.82
+5.31%
-467.65
-753.35%
-54.80
+64.25%
-153.31
Sale Of Investment
350.38
+107.33%
169.00
-2.48%
173.29
+17.25%
147.80
Financing Cash Flow
112.96
-66.51%
337.25
+115.04%
156.83
+4983.70%
3.08
Cash Flow From Continuing Financing Activities
112.96
-66.51%
337.25
+115.04%
156.83
+4983.70%
3.08
Net Common Stock Issuance
110.72
-66.59%
331.41
+123.41%
148.34
0.00
Proceeds From Stock Option Exercised
2.24
-61.68%
5.84
-31.22%
8.49
+138.90%
3.55
Net Other Financing Charges
—
—
—
-0.47
Changes In Cash
-89.09
+10.70%
-99.77
-150.71%
196.76
+295.49%
-100.65
Beginning Cash Position
149.34
-40.05%
249.11
+375.84%
52.35
-65.78%
153.00
End Cash Position
60.24
-59.66%
149.34
-40.05%
249.11
+375.84%
52.35
Free Cash Flow
-109.62
+20.78%
-138.37
-76.13%
-78.56
+20.01%
-98.22
Amortization Of Securities
-4.73
+34.09%
-7.18
-477.33%
-1.24
-217.47%
1.06
Common Stock Issuance
110.72
-66.59%
331.41
+123.41%
148.34
0.00
Issuance Of Capital Stock
110.72
-66.59%
331.41
+123.41%
148.34
0.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category